CGIX Insider Trading Activity and SEC Form 4 Filings
CGIX insider trading summary
No open-market insider purchases or sales of Cancer Genetics, Inc (CGIX) have been reported on SEC Form 4 in the past 12 months.
Latest CGIX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 31, 2019 | John Pappajohn | Director | Buy | $230K (1,000,000 @ $0.23) |
| Jan 31, 2019 | John A Roberts | Chief Executive Officer | Buy | $43K (185,436 @ $0.23) |
| Jan 31, 2019 | Michael Glenn Miles | Chief Financial Officer | Buy | $35K (150,000 @ $0.23) |
| Jan 31, 2019 | Edmund Cannon | Director | Buy | $10K (43,479 @ $0.23) |
| Jan 14, 2019 | Geoffrey E. Harris | Director | Buy | $23K (100,000 @ $0.23) |
| Jan 14, 2019 | John A Roberts | Chief Executive Officer | Buy | $23K (100,000 @ $0.23) |
| Jan 14, 2019 | John Pappajohn | Director | Buy | $225K (1,000,000 @ $0.23) |
| Dec 15, 2017 | John A Roberts | Chief Operating Officer | Buy | $24K (12,200 @ $2.00) |
| Dec 8, 2017 | John Pappajohn | Director | Buy | $279K (150,000 @ $1.86) |
| Aug 17, 2017 | John Pappajohn | Director | Buy | $214K (66,185 @ $3.23) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.